Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of Trudhesa dihydroergotamine (DHE) nasal spray and the other $50 million in the form of a credit facility. The FDA approved Trudhesa for the treatment of migraine in … [Read more...] about Impel Neuropharma secures $100 million for continued commercialization of Trudhesa nasal spray
Business
Consortium partners with RocketVax on intranasal COVID-19 vaccine development
A Swiss-German consortium led by Volker Thiel of the Institute of Virology and Immunology and the University of Bern has partnered with Swiss startup RocketVax to develop two live attenuated intranasal vaccine candidates against SARS-CoV-2 for planned Phase 1 trials. The consortium, which also includes researchers from the University of Geneva, the Freie Universität … [Read more...] about Consortium partners with RocketVax on intranasal COVID-19 vaccine development
TFF partners with US army on intranasal dry powder vaccine against SARS-CoV-2
TFF Pharmaceuticals said that the company has entered into an additional Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation for formulation of an intranasal dry powder recombinant vesicular stomatitis virus (rVSV) against SARS-CoV-2 using … [Read more...] about TFF partners with US army on intranasal dry powder vaccine against SARS-CoV-2
Sandoz acquires inhaler developer Coalesce Product Development
Declaring that it is "determined to grow its portfolio in the complex generics space," Novartis generics division Sandoz announced its acquisition of device device developer Coalesce Product Development. Coalesce's inhaler technology include MDI, breath-actuated MDI, and DPI platforms. Sandoz said that it "sees respiratory as a key pillar of its ambitious long-term … [Read more...] about Sandoz acquires inhaler developer Coalesce Product Development
Aerami Therapeutics agreement with FoxWayne has been terminated
In December 2021, inhaled drug developer Aerami Therapeutics announced that it would go public by merging with FoxWayne Enterprises Acquisition Corp, a special purpose acquisition company (SPAC). The two companies have now announced that the deal is off, effective immediately, saying, "In light of current unfavorable market conditions, Aerami and FoxWayne believe that … [Read more...] about Aerami Therapeutics agreement with FoxWayne has been terminated
TFF Pharmaceuticals partners with Catalent for DPI development and manufacturing
TFF Pharmaceuticals has partnered with CDMO Catalent for scale-up and manufacturing of dry powder formulations based on TFF's thin film freezing technology the companies have announced. The partnership will make the TFF technology available to other Catalent clients as well. Catalent notes that the TFF technology is its second addition to its inhaled dry powder … [Read more...] about TFF Pharmaceuticals partners with Catalent for DPI development and manufacturing
COPD Foundation partners with ENA Respiratory on development of pan-antiviral nasal spray
The COPD Foundation has partnered with ENA Respiratory for development of ENA's INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that it had raised A$32 million for development of INNA-051 and planned a Phase 1 trial. According to ENA, the Phase 1 study of … [Read more...] about COPD Foundation partners with ENA Respiratory on development of pan-antiviral nasal spray
Ferrer gets distribution rights to Tyvaso inhalation solution in much of the world
Ferrer has acquired the rights to distribute United Therapeutics' Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China. Terms of the deal were not disclosed. Tyvaso inhalation solution is currently approved for the treatment of … [Read more...] about Ferrer gets distribution rights to Tyvaso inhalation solution in much of the world
AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs
AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans to convert to HFO-1234ze and that a Phase 1 trial of an HFO 1234ze formulation of budesonide/ glycopyrronium/ … [Read more...] about AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs
Glenmark acquires rights to market Pulmicort Respules in Columbia
Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca's Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and supply the product to Glenmark. Glenmark Executive VP and Global Head, … [Read more...] about Glenmark acquires rights to market Pulmicort Respules in Columbia